Search
antimuscarinic deprescribing; anticholinergic deprescribing
- insufficient evidence that deprecribing antimuscarinic agents improve cognition in older adults with or without prior cognitive impairment (because the evidence from randomized controlled trials is of very low certainty)
- no evidence from randomized controlled trials that deprecribing antimuscarinic agents interventions improve other clinical outcomes includingmortality, quality of life, physical function, institutionalisation, falls, cardiovascular disease, or neurobehavioral outcomes [1]
General
medication deprescribing
References
- Taylor-Rowan M, Alharthi AA, Noel-Storr AH et al
Anticholinergic deprescribing interventions for reducing risk of cognitive
decline or dementia in older adults with and without prior cognitive impairment.
Cochrane Database Syst Rev. 2023 Dec 8;12(12):CD015405.
PMID: 38063254 Review.